OMISSION OF RADIOTHERAPY AFTER BREAST-CONSERVING SURGERY FOR WOMEN WITH BREAST CANCER WITH LOW CLINICAL AND GENOMIC RISK: 5-YEAR OUTCOMES OF IDEA

NODAL BURDEN AND ONCOLOGIC OUTCOMES IN PATIENTS WITH RESIDUAL ISOLATED TUMOR CELLS AFTER NEOADJUVANT CHEMOTHERAPY (ypN0i+): THE OPBC-05/ICARO STUDY

UGT1A1*28 POLYMORPHISM AND THE RISK OF TOXICITY AND DISEASE PROGRESSION IN PATIENTS WITH BREAST CANCER RECEIVING SACITUZUMAB GOVITECAN.

NEOADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND FLUOROPYRIMIDINE VERSUS UPFRONT SURGERY FOR LOCALLY ADVANCED COLON CANCER: THE RANDOMIZED, PHASE III OPTICAL TRIAL.